Passa al contenuto
Merck
Tutte le immagini(2)

Documenti fondamentali

Visualizza tutta la documentazione

N3136

Sigma-Aldrich

Naltrexone hydrochloride

≥99% (HPLC), powder, opioid receptor antagonist

Sinonimo/i:

Naltrexone HCl

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

100 MG
CHF 94.40
250 MG
CHF 189.00
1 G
CHF 569.00

CHF 94.40

Check Cart for Availability
Richiedi un ordine bulk
Tutte le immagini(2)

Scegli un formato

Cambia visualizzazione
100 MG
CHF 94.40
250 MG
CHF 189.00
1 G
CHF 569.00

About This Item

Formula empirica (notazione di Hill):
C20H23NO4 · HCl
Numero CAS:
16676-29-2
Peso molecolare:
377.86
Beilstein:
3580333
Numero CE:
240-723-0
Numero MDL:
MFCD00069324
Codice UNSPSC:
12352200
ID PubChem:
24278051
NACRES:
NA.77

CHF 94.40

Check Cart for Availability
Richiedi un ordine bulk

Nome del prodotto

Naltrexone hydrochloride,

Stato

powder

Ideatore

Novartis

Temperatura di conservazione

2-8°C

Stringa SMILE

Cl.Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O)CC6CC6

InChI

1S/C20H23NO4.ClH/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11;/h3-4,11,15,18,22,24H,1-2,5-10H2;1H/t15-,18+,19+,20-;/m1./s1
RHBRMCOKKKZVRY-ITLPAZOVSA-N

Informazioni sul gene

human ... OPRD1(4985) , OPRK1(4986) , OPRM1(4988) , OPRS1(10280)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Naltrexone hydrochloride has been used:
  • as an opioid antagonist, to analyse its effect on ethanol preference using Caenorhabditis elegans as a model[1]
  • to determine its effectiveness in reducing the preference for substance of abuse (SOA) like nicotine and cocaine using Caenorhabditis elegans as a model[2]
  • in the preparation of combinatorial drug, PXT3003 for treating Charcot-Marie-Tooth disease 1A (CMT1A) transgenic rat model Pmp22[3]

Azioni biochim/fisiol

Competitive antagonist for μ, κ, δ, and σ-opioid receptors; has greater oral efficacy and longer duration of action than naloxone.

Caratteristiche e vantaggi

This compound is featured on the Opioid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H302

Classi di pericolo

Acute Tox. 4 Oral

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

dust mask type N95 (US), Eyeshields, Gloves

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
BCCF6115
BCBX4989
BCCF4330
BCBV0958
BCBN1765V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 6

1 of 6

6β-Naltrexol solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

N-038

6β-Naltrexol solution

vibrant-m

BP548

Naloxone hydrochloride

β-Chlornaltrexamine dihydrochloride solid

Sigma-Aldrich

O001

β-Chlornaltrexamine dihydrochloride

Naloxone United States Pharmacopeia (USP) Reference Standard

USP

1453005

Naloxone

[Met5]Enkephalin acetate salt hydrate ≥95.0% (HPLC), powder

Sigma-Aldrich

M6638

[Met5]Enkephalin acetate salt hydrate

Methylnaltrexone bromide ≥97% (HPLC)

Sigma-Aldrich

SML0277

Methylnaltrexone bromide

Raquel Moreno-Vicente et al.
Journal of pharmaceutical and biomedical analysis, 114, 105-112 (2015-06-04)
A bioanalytical method using high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) was developed and validated for simultaneous quantification of heroin, its main metabolites and naloxone. In addition, naltrexone was detected qualitatively. This method was used to analyse human plasma samples from
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A)
Prukop T, et al.
Testing, 14(1), e0209752-e0209752 (2019)
Caenorhabditis elegans show preference for stimulants and potential as a model organism for medications screening
Engleman EA, et al.
Frontiers in Physiology, 9, 7-16 (2018)
P Bienkowski et al.
European journal of pharmacology, 374(3), 321-327 (1999-07-28)
It has been repeatedly reported that endogenous opioid pathways play an important role in ethanol drinking behaviour. In line with these findings, a non-selective opioid receptor antagonist, naltrexone, seems to reduce relapse rates in detoxified alcoholics. The aim of the
Caenorhabditis elegans as a model system to identify therapeutics for alcohol use disorders
Katner SN, et al.
Behavioural Brain Research, 365, 7-16 (2019)
Visualizza tutti i documenti correlati

Questions

Reviews

No rating value

Active Filters

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.